For example, in a previous T-cell therapy clinical trial, a TCR engineered in the CDR region for enhanced affinity to a tumour-associated antigen (MAGE-A3 peptide) showed an unexpected cross-reactivity toward a self-antigen expressed by beating cardiomyocytes; this resulted in treatment-induced patient deaths28,29. Here, MAGEA3 is linked to neoplasm.